Search - tctmd.com

Displaying 1 - 20 of 644

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Frail Patients Stand to Gain Most From Cardiac Rehab

Michael O'Riordan

November 26, 2025

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

L.A. McKeown

November 24, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Caitlin E. Cox

August 29, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say

L.A. McKeown

July 22, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Frail Patients Stand to Gain Most From Cardiac Rehab

November 2025 Dispatch for the CV Team

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

What’s Going to Be Hot at TCT 2025

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Evolocumab Gains Expanded Indication for Primary Prevention

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content